Analysis of the Incidence of Palmar-Plantar

Study design!"#$%&'()'*# )&+,$*#&$+- $)./0
Study population!1-'2'3'-')0 %&')#&'+
•4+)'#,)$5 6785&#%#'*#/5+5/8%#)+9#- %7#:8)7#&+(0;5+/<.*+,)58&5
,#8+/<.*+,);5=>1?@";5A?;5A?+&38BC5)85)&#+)53&#+$)5%+,%#&5+)5)7#5Centre&
des&maladies& du&sein Deschênes-Fabia de&l’Hôpital du&St-Sacrement du&
CHU&de&Québec&–Université Laval&&3#)6##,5+(&'- D$) EFDE5+,/5:+&%75
GD$) EFDHI
Retrospective3data3collection
Study3variables:
•Premedication!
o"#9+:#)7+$8,#5)+J#,58&+--05K:2595G5/8$#$ (night& before,&
morning and&1&hour before treatment)
o"#9+:#)7+$8,#5LM5EF5:2595D5/8$#
•PPE3gradation
oN&+/#5LL!5&#/,#$$5+,/5$6#--',256')75pain 8,57+,/$58&5O##)5
without affecting3daily3activities
oN&+/#5LLL!5&#/,#$$5+,/5$6#--',256')75intense3pain 8,5
7+,/$58&5O##)5affecting3daily3activities
METHODS
RESULTS
ANALYSIS OF THE INCIDENCE OF PALMAR-PLANTAR ERYTHRODYSTHESIA AFTER THE ADMINISTRATION OF
DOCETAXEL/TAXOTERE®USED AS AN ADJUVANT OR NEOADJUVANT BREAST CANCER THERAPY ON
PATIENTS RECEIVING A PREMEDICATION OF IV OR PER OS DEXAMETHASONE
Marie-Julie Roy1, Vanessa Blouin1, Isabelle Côté1 , Dr Julie Lemieux1,2, Anne Dionne1,2,3
1. Centre des maladies du sein Deschênes-Fabia- Hôpital du St-Sacrement - CHU de Québec- Université Laval
2. Centre de recherche du CHU de Québec – Axe Oncologie, Québec
3. Faculté de pharmacie, Université Laval, Québec
BACKGROUND
•A85%8:(+&#5)7#5',%'/#,%#58O544152&+/#5LL@LLL58,5(+)'#,)$567856#&#5
+/:','$)#&#/5+5(&#:#/'%+)'8,58O58&+-58&5',)&+*#,8.$5/#9+:#)7+$8,#5
67'-#5&#%#'*',25/8%#)+9#- %7#:8)7#&+(05',5)7#5+/<.*+,)58&5
,#8+/<.*+,) )&#+):#,)58O53&#+$)5%+,%#&I
•A85+$$#$$5)7#5,.:3#&58O5(+)'#,)$56')75%8,$#P.#,%#$5&#-+)#/5)854415
=)&#+):#,)5(8$)(8,#:#,);5/8$#5&#/.%)'8,;5/'$%8,)',.+)'8,58O5
)&#+):#,)5+,/5)&#+):#,)5:8/'O'%+)'8,C
•A85+$$#$$5)7#5(&8(8&)'8,58O5(+)'#,)$56785,##/#/5+5)&#+):#,)5
:8/'O'%+)'8,58&5+5)&#+):#,)5/'$%8,)',.+)'8,53#%+.$#58O5441I
OBJECTIVES
DISCUSSION
Docetaxel and3palmar-plantar3erythrodysthesia (PPE)
•?.)+,#8.$5&#+%)'8,$5%+,58%%.&5.,/#&5/8%#)+9#- =#&0)7#:+;5
%.)+,#8.$5#&.()'8,$5+,/5441C5',5QFR58O5)7#5(+)'#,)5=+--52&+/#$5
',%-./#/C5I5?.)+,#8.$5#&.()'8,$56')75/#$P.+:+)'8,5+&#5&#(8&)#/5',5
+((&89':+)#-05QR58O5)7#5(+)'#,)$EI5S%%8&/',25)85/'OO#&#,)5$)./'#$;5)7#5
',%'/#,%#58O54415*+&'#$5O&8:5T@QKR5+--52&+/#$5',%-./#/;5+,/5O&8:5
F@HR5O8&52&+/#$5LLL58&5:8&#E@HI5A7#&#5'$ ,85:#,)'8,58O54415',5$)./'#$
%8,/.%)#/ 8,5/'OO#&#,) /8%#)+9#- (&8)8%8-$ ',5+/<.*+,)53&#+$) %+,%#&5
)7#&+(0Q@TI5A7#5+.)78&$58O5)7#5$)./05#*+-.+)',25A?+&38 &#(8&)#/5+,5
',%'/#,%#58O5FR58O544156')75)7#'&5(+)'#,)$UI5?78.+, #)5+-5/'/5,8)5
&#(8&)5+5/'OO#&#,%#5',5)7#5',%'/#,%#58O54415/#(#,/',258,5)7#5
/#9+:#)7+$8,#5(&#:#/'%+)'8,5&#2':#,5=4V58&5LMCDI5S5$)./0
%8,/.%)#/ +)58.& %#,)#&5%8:(+&#/ )7#5',%'/#,%#58O54415',5(#&58$5
/#9+:#)7+$8,# &#2':#, *#&$.$5LM5&#2':#, +,/5$786#/ +,5',%'/#,%#5
8O544158O5FR5+,/5DFR5&#$(#%)'*#-0KI5
Breast3cancer!
•A7#5:8$)5O&#P.#,)-05/'+2,8$#/5%+,%#&5',5?+,+/+I
•W8&#5)7+,5DFFF5,#65/'+2,8$'$5+,,.+--05+)5)7#5Centre&des&maladies& du&sein
Deschênes-Fabia de&l’Hôpital du&St-Sacrement du&CHU&de&Québec& –
Université Laval.
Adjuvant3chemotherapy!
•"8%#)+9#-XA+98)#&#Y5 '$5+5O&#P.#,)-05.$#/5%7#:8)7#&+(05+2#,)5O8&5+/<.*+,)5
3&#+$)5%+,%#&5)&#+):#,)I
•S/<.*+,)5%7#:8)7#&+(05(&8)8%8-$5+&#!5>1?@";5A?5+,/5A%+&38I
Premedication!
•"8%#)+9#- ,##/$5)853#5+/:','$)#&#/56')75+5/#9+:#)7+$8,#5(&#:#/'%+)'8,5
)+J#,58&+--05=K:2595G5/8$#$C5$)+&)',25)7#5,'27)53#O8&#5)7#5)&#+):#,)5.(5
.,)'-5)7#5)&#+):#,)5+,/5+O)#&5)7#5)&#+):#,)5=K5:2595G5/8$#$CI5L,)&+*#,8.$5
=LMC5/#9+:#)7+$8,#5=EF:2595D5/8$#C5+,/5+O)#&5)7#5)&#+):#,)5=K5:2595G5
/8$#$C56+$5+-$85.$#/5',58.&5%#,)#&5+O)#&5)7#5(.3-'%+)'8,58O5)7#5$)./05305
?78.+, et&al. ',58&/#&5)85#,$.&#5+53#))#&5)&#+):#,)5+/7#&#,%#DI5
INTRODUCTION
REFERENCES
•A7#5%7+&+%)#&'$)'%$58O5)7#5)6852&8.($5+&#5%8:(+&+3-#5
#9%#()5O8&5)7#5B1ZE[#.5$)+).$5+,/5)7#5(&#$#,%#58O5
-0:(78*+$%.-+& ',*+$'8,I5\#5/85,8)53#-'#*#5)7+)5
)7#$#5/'OO#&#,%#$5+-8,#5%+,5#9(-+',5)7#583)+',#/5
&#$.-)$I
•A7#&#5'$5:8&#54415+O)#&5%0%-#5E5O8&5(+)'#,)$56785
&#%#'*#/5LM5/#9+:#)7+$8,#5%8:(+&#/5)854#&58$
/#9+:#)7+$8,#5O8&5+--5$)./'#/52&+/#$5=LL5+,/5LLLCI5
W8&#5(+)'#,)$56785&#%#'*#/5LM5/#9+:#)7+$8,#57+/5
%8,$#P.#,%#$5',5&#-+)'*#5)85)7#'&5)&#+):#,)I5Z#$.-)$5
&#:+',5$'2,'O'%+,)567#,5)7#5(+)'#,)$56785%7+,2#/5
(&#:#/'%+)'8,5&#2':#,5/.&',25)7#'&5)&#+):#,)5+&#5
#9%-./#/I5]+:#56')75)7#5(+)'#,)$567857+/5/8$#5
:8/'O'%+)'8,$58&5)&#+):#,)5(8$)(8,#:#,)$I5
•SO)#&5%0%-#5G;5)7#52&8.($53#%+:#5$:+--#&;5+,/5')5
3#2+,57+&/#&5)85/&+65%8,%-.$'8,$I5A7'$5':(8&)+,)5
/':',.)'8,5'$53#%+.$#5(+)'#,)$56785&#%#'*#/5>1?@"5
/'/5,8)57+*#5#,8.275%8--#%)#/5',O8&:+)'8,5',5)7#'&5
(+)'#,)$^5O'-#5+O)#&5%0%-#5G5)853#5',%-./#/5O8&5O.&)7#&5
+,+-0$'$I5
•A7#5&#)&8$(#%)'*#5$)./05/#$'2,5#9(-+',$5)7#5+38*#5
)7&##56#+J,#$$#$I5
•HR58O5)7#5(+)'#,)$5',5)7#5LM5/#9+:#)7+$8,#52&8.(5
7+/5)85/'$%8,)',.#5)&#+):#,)58&5:8/'O05)7#5
%7#:8)7#&+(05&#2':#,5*$5FR5',5)7#54#&58$
/#9+:#)7+$8,#5&#2':#,I5A7'$5+,+-0$'$5'$5/#$%&'()'*#5
+,/5)7#&#O8&#;5,85%8,%-.$'8,5%+,5305/&+6,5O&8:5')I5
S-)78.27;5+5%#&)+',5(&#8%%.(+)'8,5+&8$#5O&8:5)7#5
&#$.-)$53#%+.$#5)7#$#5(+)'#,)$5+&#5)&#+)#/5',5+,5
+/<.*+,)5%8,)#9)I55
•A7#&#5$##:$5)853#5+5%.:.-+)'*#5#OO#%)58O5)7#5%0%-#$5
3#%+.$#5)7#54415+((#+&$58,-05+)5%0%-#5EI5A7#5
:#%7+,'$:5#9(-+',',25)7#5+.2:#,)+)'8,58O5)7#54415
',5&#-+)'8,5)85)7#5&8.)#58O5+/:','$)&+)'8,58O5)7#5
/#9+:#)7+$8,#5'$5.,J,86,I5A7#5+,)'@',O-+::+)8&05
#OO#%)58O5/#9+:#)7+$8,#54#&58$ :+03# :8&#5
':(8&)+,)5$',%#5')5'$5+/:','$)#&#/5+)5-#+$)5DE578.&$5
3#O8&#5)7#5+/:','$)&+)'8,58O5/8%#)+9#-I
1. Chouhan JD,&Herrington&JD.&Single&premedication&dose&of&dexamethasone&
20&mg&IV&before&docetaxel administration.&J&Oncol Pharm Pract 2011 ;&17:&
155-9.
2. Taxotere (docétaxel).&Monographie&de&produit.&Laval,&QC,&Canada :&
Sanofi-Aventis ;&Date&de&révision&12&juin&2015.
3. Degen A,&Alter&M,&Schenck F&et&al.&The&hand-foot-syndrome&associated
with medical tumor therapy –classification&and&management.&JDDG&
2010 ;&8 :&652-61.
4. Poi&MJ&,&Berger&M,&Lustberg M&et&al.&&Docetaxel-induced&skin&toxicities&in&
breast&cancer&patients&subsequent&to&paclitaxel&shortage:&a&case&series&
and&literature&review.&Support&Care&Cancer&2013&21:2679–2686.
5. Jones&S,&Holmes&FA,&O’Shaughnessy J&et&al.&Docetaxel With&
Cyclophosphamide& Is&Associated&With&an&Overall&Survival&Benefit&
Compared&With&Doxorubicin&and&Cyclophosphamide:& 7-Year&Follow-Up&of&
US&Oncology&Research&Trial&9735.&J&Clin&Oncol 2009 ;&27(8):1177-83.
6. Roché&H,&Fumoleau P,& Spielmann M&et&al.&Sequential&Adjuvant&Epirubicin-
Based&and&Docetaxel Chemotherapy&for&Node-Positive&Breast&Cancer&
Patients:&The&FNCLCC& PACS&01&Trial.&J&Clin&Oncol 2006 ;&24&(36) :&5664-71.
7. Slamon D,&Eiermann W,& Robert&N&et&al.&Adjuvant& Trastuzumab in&HER2-
Positive&Breast Cancer.&N&Engl J&Med&2011 ;&365&(14) :&1273-83.&(article&
parlant&TCarbH)
8. Laroche&J.&Evaluation de&l’efficacité&d’une&dose&unique&de&20&mg&de&
dexaméthasone iv&avant&l’administration&de&docetaxel.&Essai&présenté&
pour&l’obtention&de&grade&de&maître&ès&sciences.&&Université&Laval.&Août&
2012.
CONCLUSION
A7#583)+',#/5&#$.-)$5-#/5.$5)85&#',)&8/.%#5)7#5.$#58O5
/#9+:#)7+$8,#54#&58$ +$5)7#5$)+,/+&/5(&#:#/'%+)'8,56')75
/8%#)+9#- %7#:8)7#&+(0I5"#9+:#)7+$8,#5LM5$78.-/53#5
.$#/5+$5+,58()'8,567#,5,8,583$#&*+,%#58%%.&$;5.,)'-5
O.&)7#&5',O8&:+)'8,5'$5+*+'-+3-#I5